Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?

A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.

Related Keywords

Quebec ,Canada ,Mark Sorin ,Mcgill University ,Morris Goodman Cancer Institute ,European Medicines Agency ,Drug Administration ,European Medicines ,Non Small Cell Lung Cancer ,Nsclc ,Lung Cancer ,Ung Carcinoma ,Ancer Of The Lung ,Neoadjuvant ,Meta Analysis ,Chemotherapy ,Small Cell Lung Cancer ,At Cell Lung Cancer ,Clc ,Biologic Therapy ,Iologics ,Toxicology ,Toxicity ,Poisoning ,Toxins ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Europe ,European ,Tumor ,Us Food And Drug Administration ,